Related Experiment Video
Updated: Oct 23, 2025

Anatomical Reconstructions of the Human Cardiac Venous System using Contrast-computed Tomography of Perfusion-fixed Specimens
Published on: April 18, 2013
Major Adverse Renal and Cardiovascular Events following Intra-Arterial Contrast Media Administration in Hospitalized
Peter McCullough1, Chaan S Ng2, Michael Ryan3
1Texas A & M University College of Medicine, Baylor Dallas Campus, Dallas, Texas, USA.
Insights
Iso-osmolar contrast media (IOCM) use is linked to fewer adverse renal and cardiovascular events compared to low-osmolar contrast media (LOCM) in high-risk patients. This real-world data confirms IOCM
Area of Science:
- Cardiovascular Medicine
- Nephrology
- Radiology
Background:
- Clinical studies suggest iso-osmolar contrast media (IOCM) may reduce adverse renal and cardiovascular outcomes compared to low-osmolar contrast media (LOCM).
- Real-world data is needed to confirm these findings in high-risk patients undergoing intra-arterial procedures, particularly those with comorbidities.
- Major Adverse Renal and Cardiovascular Events (MARCE) association with contrast type in at-risk populations requires robust analysis.
Purpose of the Study:
- To retrospectively assess and compare MARCE rates between IOCM and LOCM in at-risk patients receiving iodinated intra-arterial contrast media.
- To analyze real-world inpatient data to validate the safety profile of IOCM versus LOCM in specific comorbid patient subgroups.
Main Methods:
- Utilized the Premier Healthcare Database to identify patients undergoing procedures with intra-arterial IOCM or LOCM.
- Formed patient subgroups based on comorbidities: diabetes, heart failure, chronic kidney disease (CKD) stages 1-4, CKD 3-4, and chronic total occlusion (CTO).
- Compared MARCE (composite of AKI, dialysis, myocardial infarction, stroke, stent occlusion, death) using multivariable regression analysis.
Main Results:
- In a cohort of 536,013 inpatient visits, IOCM use was associated with significantly lower MARCE rates than LOCM in patients with CKD 1-4, CKD 3-4, diabetes, or heart failure.
- Greatest absolute risk reduction (ARR) of 2.4% was observed in CKD 3-4 patients (NNT=43), with further ARR of 3.5% in combined diabetes and CKD 3-4 (NNT=29).
- Significant risk reduction was also noted for IOCM in patients with CTO revascularization (ARR=1.6%, NNT=62).
Conclusions:
- Intra-arterial IOCM administration is associated with reduced MARCE rates compared to LOCM in at-risk patient populations.
- The benefits of IOCM are particularly pronounced in patients with combined diabetes and CKD 3-4, and in those undergoing CTO revascularization.
- This real-world evidence supports the use of IOCM for improved outcomes in vulnerable patients undergoing intra-arterial procedures.
Introduction:
Several clinical studies and meta-analyses have demonstrated lower incidence of adverse renal and cardiovascular outcomes associated with the use of iso-osmolar contrast media (IOCM) than low-osmolar contrast media (LOCM) in patients with variable risk profiles undergoing intra-arterial interventional procedures. However, the association of contrast-type and major adverse renal and cardiovascular events (MARCE) has not been studied via comprehensive and robust real-world data analyses in patients with comorbid conditions considered at risk for post-procedural acute kidney injury (AKI). The objective of this study was therefore to retrospectively assess the MARCE rates comparing IOCM with LOCM in at-risk patients receiving iodinated intra-arterial contrast media using a real-world inpatient data source.
Methods:
Patients who underwent a diagnostic or treatment procedure with intra-arterial IOCM or LOCM administration were identified using the Premier Healthcare Database. Patient subgroups including those with diabetes, heart failure, chronic kidney disease (CKD) stages 1-4, CKD 3-4, or diagnosis of chronic total occlusion (CTO) were formed. Subgroups with combinations of diabetes and CKD 3-4 with and without CTO were also investigated. We compared the primary endpoint of MARCE (composite of AKI, AKI requiring dialysis, acute myocardial infarction, stroke/transient ischemic attack, stent occlusion/thrombosis, or death) after IOCM versus LOCM administration via adjusted multivariable regression analyses.
Results:
A total of 536,013 inpatient visits met the primary inclusion and exclusion criteria (IOCM = 133,192; LOCM = 402,821). After multivariable modeling, the use of IOCM was associated with a significantly lower incidence of MARCE than LOCM in patients with CKD 1-4, CKD 3-4, diabetes, or heart failure, with greatest absolute risk reduction (ARR) of 2.4% (p < 0.0001) in CKD 3-4 patients (relative risk reduction [RRR] = 13.8%, number needed to treat [NNT] = 43). Additionally, ARR associated with IOCM increased to 3.5% (p < 0.0001) in patients with combined comorbidities of diabetes and CKD 3-4 (RRR = 19.1%, NNT = 29). Statistically significant risk reduction was also found for the use of IOCM among patients who underwent revascularization for CTO (ARR = 1.6% [p < 0.0001], RRR = 22.3%, NNT = 62).
Conclusion:
Intra-arterial administration using IOCM in at-risk patients is associated with lower rates of MARCE than the use of LOCM. This difference is especially apparent in patients with a combination of CKD 3-4 and diabetes and in patients with CTO, providing real-world data validation with meaningful NNT in favor of IOCM.
More Related Videos
Related Concept Videos
Cardiac Catheterization I: Pre-Procedure Overview
Imaging Studies VII: Vascular Imaging
Radiological Investigation I: X-ray and CT
Imaging Studies for Cardiovascular System V: CT
Imaging Studies III: Computed Tomography
Cardiac Catheterization IV: Nursing Management

